CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship
Pioneering company unlocking transfer RNA (tRNA) biology and
pioneering tRNA therapeutics to regulate the protein universe and
resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical
and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was
the Director of the Office of Rare Diseases Research (ORDR) at the
National Center for Advancing Translational Sciences (NCATS),
National Institutes of Health (NIH), whose mission is to advance
rare diseases research through a variety of research programs.
Prior to ORDR, she worked at the U.S. Food and Drug Administration
(FDA) Center for Drug Evaluation and Research (CDER), where she
founded the Rare Diseases Program and predominantly focused on rare
diseases drug review.
"Anne has been an exceptional force in government organizations,
first at the FDA and then at the NIH, to propel rare disease
research, translational science, and drug development," said
Lovisa Afzelius, Ph.D., MBA,
Origination Partner at Flagship Pioneering and Founding CEO of
Alltrna. "We are thrilled she has joined our team to lead Alltrna's
strategy for regulatory and medical research as we leverage tRNA
biology as a platform approach to treat many diseases with a single
medicine."
"I'm so impressed with the vision and motivation of the team at
Alltrna to pursue a 'many-diseases-at-a-time' strategy with the
focus of making a significant impact on the treatment of rare
diseases," said Dr. Pariser. "As a therapeutic mechanism, tRNA has
this unique potential to treat thousands of different diseases with
a precision medicine approach. Alltrna's deep and systematic
exploration of tRNA biology creates a very exciting way to explore
the nearly limitless potential of tRNA medicines."
During her tenure at ORDR, Dr. Pariser oversaw the Rare Diseases
Clinical Research Network (RDCRN), a network of rare diseases
research consortia focusing on research programs into more than 200
different rare diseases and other research programs. Additional
research programs included the PaVe-GT gene therapy development
program, which seeks to treat four ultra-rare diseases using a
platform approach, grant programs to speed rare disease diagnoses
and many-diseases-at-a-time strategies, and rare diseases
informatics. Prior to ORDR, Dr. Pariser held several roles over her
16-year career at the FDA and most notably founded the Rare
Diseases Program, which focused on developing regulatory science,
policy, and processes intended to facilitate rare disease drug
development and review. Dr. Pariser received her medical degree
from Georgetown University School of
Medicine and completed her Internal Medicine Internship and
Residency at Georgetown University
Medical Center. She is Board certified in Internal Medicine.
About Alltrna
Alltrna unlocks tRNA biology to correct
disease. The company's platform incorporates AI/ML tools to learn
the tRNA language and deliver diverse programmable molecules with
broad therapeutic potential. Alltrna has an unprecedented
opportunity to advance a single tRNA medicine to unify treatment
across a wide range of diseases with the same underlying genetic
mutation. Alltrna was founded in 2018 by Flagship Pioneering. For
more info, visit www.alltrna.com.
About Flagship Pioneering
Flagship Pioneering
conceives, creates, resources, and develops first-in-category
bioplatform companies to transform human health and sustainability.
Since its launch in 2000, the firm has, through its Flagship Labs
unit, applied its unique hypothesis-driven innovation process to
originate and foster more than 100 scientific ventures, resulting
in more than $140 billion in
aggregate value. To date, Flagship has deployed over $2.6 billion in capital toward the founding and
growth of its pioneering companies alongside more than $19 billion of follow-on investments from other
institutions. The current Flagship ecosystem comprises 42
transformative companies, including Axcella Health
(Nasdaq: AXLA), Codiak BioSciences (Nasdaq: CDAK), Denali
Therapeutics (Nasdaq: DNLI), Evelo Biosciences
(Nasdaq: EVLO), Foghorn Therapeutics (Nasdaq: FHTX),
Indigo Ag, Kaleido Biosciences
(Nasdaq: KLDO), Moderna (Nasdaq: MRNA), Omega
Therapeutics (Nasdaq: OMGA), Rubius Therapeutics
(Nasdaq: RUBY), Sana Biotechnology (Nasdaq: SANA), Seres
Therapeutics (Nasdaq: MCRB), and Sigilon Therapeutics
(Nasdaq: SGTX).
Media Contact for Alltrna
Jessica Yingling, Ph.D., Little Dog
Communications Inc., jessica@litldog.com, +1.858.344.8091
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alltrna-appoints-rare-disease-clinical-research-expert-dr-anne-pariser-as-vice-president-medical-and-regulatory-affairs-301490197.html
SOURCE Alltrna
